In this context, it will also be very important to evaluate whether CFTR modulator therapy might influence innate and adaptive immune dysregulation in CF, and eventually synergize with anti-inflammatory therapy in modulating the altered inflammatory/immune response to chronic infection in CF. The gene discussed is CFTR; the disease is cystic fibrosis.